Skip to main content

COVID-19 Updates: Get the latest on vaccine information, in-person appointments, video visits and more. Learn More >>

Study of ARQ 092 in Subjects With PIK3CA-related Overgrowth Spectrum and Proteus Syndrome (MOSAIC)


This is an open label, Phase 1/2 study of oral ARQ 092 (Miransertib) administered to subjects at least 2 years of age with PIK3CA-related Overgrowth Spectrum (PROS) and Proteus syndrome (PS) (MOSAIC).

Eligibility Criteria

  • Ages Eligible for Study: 2 – 21 years old
  • Sexes Eligible for Study: All

Detailed inclusion and exclusion criteria as listed on


Principal Investigator:

Dr. Ionela Iacobas
Medical Director, Vascular Anomalies Center, Texas Children's Hospital
(832) 824-4819

Related Articles

ArQule Announces First Patient Dosed in Registrational MOSIAC Trial of Miransertib for the Treatment of Proteus Syndrome and PIK3CA-related Overgrowth Spectrum (October 2, 2019 - BioSpace)